iVexSol’s mission is to improve patients lives by developing transformative vector production technologies that will enable and accelerate the discovery of new medicines and increase patient access to vital cell and gene therapies (CGTs).
At present, the cost and speed of development for such life-saving therapies are highly impacted by technical limitations related to vector production. Next generation therapeutics are being restricted by outdated manufacturing technology. iVexSol was founded on the discovery of how to uniquely produce stable lentiviral vector producer cell lines and is committed to solving the vector shortage and improve access to critically needed therapies.
Meet the Founders
Rodney L. Rietze, Ph.D.
Co-founder and CEO
Former Director of Strategic Development and Innovation, Novartis
Co-Founder & Principal Investigator, Queensland Brain Institute, Australia
Dr. Rietze’s academic career focused on discovering the biological mechanisms that underpin the regenerative capacity of the central nervous system. In 2008, he transitioned to industry to apply these learnings to develop a novel class of therapeutics, cell and gene therapies, at the newly created Pfizer Regenerative Medicine (Cambridge, UK). He later joined Novartis, where he helped develop novel bioprocesses, analytics and enabling technologies to support the clinical development and commercial launch of KymriahTM, the first FDA-approved personalized CAR-T cell therapy. In continuation of his life-long pursuit to deliver innovative technologies and novel therapeutics to expand and transform the treatment of disease, Dr. Rietze co-founded iVexSol in 2019, where he uses his two decades of technical, operational and strategic leadership experience to guide and support an outstanding team as they work to transform the manufacture of viral vectors.
Dr. Rietze holds a B.Sc. and M.Sc. from The University of Calgary and a Ph.D. from The University of Melbourne.
Michael Greene, M.D.
Co-founder and CSO
Former Executive Director of Stem Cell Gene Therapeutic Program, Mustang Bio
Former Team Leader of Next Generation Cell & Gene Therapy Development, Novartis
Dr. Greene has over 25 years of industrial and academic experience in the development of cell and gene therapies. Before co-founding iVexSol, Dr. Greene was a practicing Hematologist/Oncologist, specializing in Bone Marrow Transplant and Stem Cell Therapy. He chose this specialty specifically to perform clinical gene therapy, and as the emerging field clearly required more development, he began creating new technologies. He became a co-creator of the first and only stable lentiviral producer cell line currently used in IND-approved clinical trials, and he is a co-inventor on 7 cell and gene therapy focused patents including lentiviral vector manufacturing and next-generation CAR-T manufacturing. He has worked on both small and large teams creating life-changing living drugs including the first FDA approved cell and gene therapeutic Kymriah®️, the first rapidly manufactured CAR-Ts YTB323 and PHE885, and the hematopoietic stem cell drug for X-SCID (a.k.a. “bubble boy disease”) MB-107. Dr. Greene co-founded iVexSol to advance the field of gene therapy and bring cures to those previously without hope.
Dr. Greene received his BS from Clarkson University, MS in Cell & Molecular Biology from WVU, his MD from the University of Connecticut Medical School, completed his Internal Medicine residency at Dartmouth-Hitchcock Medical Center, and his Hematology/Oncology Fellowship at Norris Cotton Center.
Strategic Advisory Board
Joe Gentile, MBA, M.Eng.
Board Member / Advisor
Mr. Gentile is an operating executive, board member, investor and strategy advisor with over 30 years of experience in medical devices, diagnostics and life science tools. Mr. Gentile began his career at the HP Medical Products Group where he spent 10 years in engineering, marketing and corporate development. Later in his career he spent 14 years at Becton Dickinson in both corporate strategy and global business unit general management roles. More recently, he was CEO and Board member at Cellero Biosciences (acquired by Charles River Labs) and Stemgent Inc (acquired by the ReproCell Group of Japan). He holds a B.Sc. from MIT, MBA from Boston University Questrom School of Business and a M.Eng. from Boston University College of Engineering.
Michael Singer, M.D., Ph.D.
Strategic Advisory Board
Dr. Singer is a serial life sciences entrepreneur, physician-scientist, and investor. He serves as CSO at Cartesian Therapeutics and was co-founder of Topokine and HealthHonors. He also led development of several monoclonal antibody therapies at Novartis. His research spans over 25 years with numerous high-profile publications (including a first-author paper in Nature) and over 100 patents. Mike serves on the clinical faculty and as an entrepreneur-in-residence at Yale University and has Board seats on a number of public/private life science companies as well as the Boston Museum of Science. He holds a B.Sc., M.D., and Ph.D. from Yale and completed residency at Harvard.
William Mercer, B.Sc.
Strategic Advisory Board
Bill Mercer has over 30 years’ experience in blood banking, medical devices and the development of novel cell-based therapies. Bill was an advisor at Cell One PARTNERS and a Non-Executive Director at Key Biologics, LLC where he offered strategic guidance in the collection of cells for research use. During his 8-year tenure at Terumo BCT he was responsible for the global automated apheresis collections business global strategy, product development and prioritization, and matrix sales responsibility with regional commercial leaders, business development and was a member of the Executive Management team.
Amitabha Deb, Ph.D.
SVP, Process & Analytical Sciences
Amitabha has over 30 years of experience in academics and the pharma industry after completing his postdoctoral training at Cleveland Clinic in molecular mechanisms of malignant transformation by human viruses. His research interests were focused on gene regulation and the development of therapeutic antisense oligonucleotides.
As Senior Vice President of Process Sciences and MS&T at iVexSol, Amitabha will lead the efforts to develop closed system automated processes for Lentiviral production using iVexSol proprietary stable cell lines. He is implementing processes with intelligent technologies and devices for improved understanding of product quality attributes of lentiviral vectors for Gene therapy applications. His team is focused on developing integrated analytical and correlational capabilities while accelerating the integration of novel technologies.
Previously in the pharma industry, Amitabha was involved in transitioning a portfolio of biologics products from R&D to Clinical Development at Novartis Pharma. He led the lentiviral vector gene therapy team for Kymriah, the first approved gene therapy product in the US. His contribution to the development of Kymriah includes developing the next generation of lentiviral processes for CAR-T applications. He patented several formulations for the stabilization of Lentiviral vectors and contributed significantly to process and analytical development for clinical and commercial programs including Kymriah, Zinplava, Rabishield, Cosentyx, and Zinc finger nuclease (ZFN) mediated gene-edited products for beta-thalassemia and Sickle Cell Disease. He has also led Technical Development teams at Bioverativ, Sanofi, Ring Therapeutics, Aruvant, and other startup companies focusing on diverse cell and Gene therapy applications.
Senior Vice President, Operations
Mr. Sean Brown comes to iVexSol with over 30 Years in the biopharmaceutical industry with technical leadership experience developing Cell Gene Therapy clinical and commercial operations for industry leaders. Prior to joining iVexSol he was a Partner with BW Design Group, an engineering consulting firm with responsibility for engineering, construction, and validation for CGT projects. He has also had leadership roles with Bristol-Myers Squibb’s radionuclide division in global facilities and operations, and at AstraZeneca leading Technical Services in the tech transfer, scale up, and regulatory submissions for clinical and commercial manufacturing of aseptic, small molecule formulations for parenteral and sterile products. He graduated from University of Warwick’s, Business Process Management program and holds a B.Sc. in Engineering from the University of Massachusetts.
Edwin L Beale, B.Sc., M.Sc., MBA
VP, Business Development
Mr. Edwin Beale comes to iVexSol with over 25 years in the biomanufacturing industry across various modalities, mainly focusing on large molecules (peptides, proteins – both microbial & Mab based), DNA Antisense & most recently CGTs. Prior to joining iVexSol, Edwin was VP of Business Development at Catalent Biologics (Formerly MaSTherCell). During his time at Cytovance Biologics, Edwin served as VP, directing sales and marketing while supporting M&A integration endeavors. Mr. Beale earned his MBA from the UNC Kenan-Flagler Business school. He also holds a B.Sc. and a M.Sc. from Tuskegee University.
Lana Parent, B.A., M.A.
Executive Director, R&D Operations
Lana brings over 20 years of drug development experience to lead our R & D operations. In her outstanding career she has brought no less than three anti-cancer drugs to successful commercialization: Halaven® (an active drug to fight breast cancer), Velcade® (a first-in-class proteosome blocking agent for the treatment of Multiple Myeloma), and finally, Kymriah® the ground-breaking, first-in-class, CAR-T therapy for the treatment of pediatric Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma. Throughout her career she has acquired a vast knowledge of laboratory science, has a keen attention to details, and an unwavering resolve.
Lana has a B.A. from the College of Our Lady of the Elms, Massachusetts and a M.A. from The University of Massachusetts (Amherst)